Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies

Clinical trial NCT07584889 · RECRUITING

Trial details

NCT number: NCT07584889
Sponsor: Shenzhen University General Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B Cell Lymphoma Acute Lymphoblastic Leukemia Acute Myeloid Leukemia

Start date: 2024-04-20
Primary completion: 2029-04-19
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.